8-K: Cocrystal Pharma Holds Annual Meeting, Elects Directors
Annual Meeting Results
Cocrystal Pharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of five directors and ratification of its independent auditor.
Summary
- Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026.
- Stockholders voted to elect five members to the Board of Directors.
- The appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- A proposal to adjourn the meeting was rendered moot due to sufficient votes for the other proposals.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance activities with successful outcomes.
Positives
- Successful election of all five nominated directors to the Board.
- Strong ratification of Weinberg & Company as the independent auditor for the upcoming fiscal year.
- Sufficient votes were cast to approve key proposals, avoiding the need for adjournment.
Future Outlook
The filing does not contain specific forward-looking statements or guidance beyond the ratification of the auditor for the fiscal year ending December 31, 2026.
Industry Context
StockSavvy.ai notes that the smooth execution of annual meetings and director elections is a standard governance practice for publicly traded companies, indicating operational stability.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Dr. Roger Kornberg | July 14, 2026 | Election by stockholders |
| Director | N/A | Dr. Phillip Frost | July 14, 2026 | Election by stockholders |
| Director | N/A | Mr. Fred Hassan | July 14, 2026 | Election by stockholders |
| Director | N/A | Mr. Richard C. Pfenniger, Jr. | July 14, 2026 | Election by stockholders |
| Director | N/A | Mr. Steven Rubin | July 14, 2026 | Election by stockholders |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of five directors to the Board. | July 14, 2026 | Standard procedure for board continuity and oversight. |
| Auditor Ratification | Ratification of Weinberg & Company as independent auditor. | July 14, 2026 | Ensures independent financial oversight for the upcoming fiscal year. |
Stakeholder Impact
- Shareholders: Confirmation of board leadership and independent financial oversight provides assurance.
- Employees: Stability in leadership and governance can contribute to a stable operating environment.
- Creditors: Ratification of auditor reinforces financial transparency and reporting integrity.
Next Steps
- The newly elected directors will serve until the next annual meeting of stockholders.
- Weinberg & Company will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-05-27 | Date of filing of the Company's definitive proxy statement. |
| 2026-07-14 | Date of the 2026 Annual Meeting of Stockholders. |
| 2026-07-17 | Date of the report signature. |
| 2026-12-31 | Fiscal year end for which Weinberg & Company was appointed as independent auditor. |
Keywords
Cocrystal Pharma, 8-K Filing, Annual Meeting, Board of Directors, Stockholder Vote, Independent Auditor, Weinberg & Company, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.